The Evaluation Of Use of Belimumab in Routine Care SEttings in Lupus Nephritis (LN): the OBSErve-LN Study
The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in belimumab treated participants.
• Participants to provide a signed informed consent at the time of enrollment per protocol,
• Male or female aged 18 or over at initiation of belimumab,
• Participants received belimumab for the treatment of active LN prescribed as per local label in combination with standard immunosuppressive therapy/ies at initiation of belimumab,
• Participants initiated belimumab 6 to 24 months prior to study enrollment,
• Accessibility of medical records starting at belimumab initiation (including accessibility of medical records for the prior 12 months and confirmatory biopsy within the prior 24 months from belimumab initiation),
• Biopsy-confirmed diagnosis of active LN in the two-years prior to the initiation of belimumab
‣ Class III (focal LN) with or without Class V (membranous LN),
⁃ Class IV (diffuse LN) with or without Class V,
⁃ Class V.